Table 3.
The NL4.3 laboratory-adapted pseudovirus was neutralized by seed extracts from each transgenic line
| Line | Crude ID50 (reciprocal dilution) | Apparent IC50 (ng/mL) for individual components | ||
| 2G12 | CV-N | GRFT | ||
| 2G12-1 | <25 | >144 | ||
| 2G12-2 | <25 | >119 | ||
| 2G12-3 | <25 | >148 | ||
| CV-N-1 | <25 | >220 | ||
| CV-N-2 | 234 | 2.50 | ||
| CV-N-3 | 86 | 2.30 | ||
| GRFT-1 | 11,376 | 0.70 | ||
| GRFT-2 | 4,808 | 1.35 | ||
| 1 | 8,892 | 0.12 | 1.06 | |
| 2 | 755 | 0.66 | 0.53 | |
| 3 | — | — | — | — |
| 4 | <25 | >116 | >8 | |
| 5 | <25 | >20 | >8 | |
| 6 | <25 | >120 | >8 | |
| 7 | 4,178 | 0.24 | 0.24 | |
| 8 | 1,734 | 2.13 | 1.85 | |
| 9 | 7,482 | 0.55 | 0.01 | 0.09 |
| 10 | 17,061 | 0.14 | 0.01 | 0.12 |
| 11 | 5,585 | 0.77 | 0.05 | 0.29 |
| Wild type | <25 | |||
Values represent the ID50 for each extract (reciprocal dilution) and apparent IC50 (ng/mL) for each component. The sample from line 3 was compromised in transit and was not tested.